{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:06:34Z","timestamp":1779062794327,"version":"3.51.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,17]]},"DOI":"10.7759\/cureus.109045","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:33:26Z","timestamp":1779060806000},"source":"Crossref","is-referenced-by-count":0,"title":["A Severe Symptomatic Case of Amyloid-Related Imaging Abnormalities After Donanemab Infusion"],"prefix":"10.7759","author":[{"given":"Nikitha","family":"Harikumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taysir","family":"Al Janabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karampal K","family":"Mand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al.. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023, 330:512-27. 10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85377","article-title":"A systematic review of the efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease","volume":"17","author":"Chundu UC","year":"2025","unstructured":"Chundu UC, Thiriveedhi SR, Bhatti C, Mupparaju JS, Otinashvili N, Gelishvili E. A systematic review of the efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease. Cureus. 2025, 17:e85377. 10.7759\/cureus.85377","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer JA","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, et al.. Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025, 82:461-9. 10.1001\/jamaneurol.2025.0065","journal-title":"JAMA Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2024.0105","article-title":"Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: recent updates on clinical and imaging features and MRI monitoring","volume":"25","author":"Jeong SY","year":"2024","unstructured":"Jeong SY, Suh CH, Kim SJ, Lemere CA, Lim JS, Lee JH. Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: recent updates on clinical and imaging features and MRI monitoring. Korean J Radiol. 2024, 25:726-41. 10.3348\/kjr.2024.0105","journal-title":"Korean J Radiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100519","article-title":"Memory consolidation and ARIA in individuals receiving anti-amyloid monoclonal antibodies","volume":"13","author":"Haut MW","year":"2026","unstructured":"Haut MW, Teixeira CV, Worhunsky PD, et al.. Memory consolidation and ARIA in individuals receiving anti-amyloid monoclonal antibodies. J Prev Alzheimers Dis. 2026, 13:100519. 10.1016\/j.tjpad.2026.100519","journal-title":"J Prev Alzheimers Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1599048","article-title":"Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer's disease","volume":"16","author":"Wang H","year":"2025","unstructured":"Wang H, Pan J, Zhang M, Tan Z. Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer's disease. Front Pharmacol. 2025, 16:1599048. 10.3389\/fphar.2025.1599048","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.22541\/au.175811469.99303481\/v1","article-title":"Donanemab-associated amyloid-related imaging abnormalities presenting as acute stroke mimic and seizure [PREPRINT]","author":"Kesavamoorthy NB","year":"2025","unstructured":"Kesavamoorthy NB, N. Zaidi, S. Aggarwal, A. Salazar, B. Desai, A. Donanemab-associated amyloid-related imaging abnormalities presenting as acute stroke mimic and seizure [PREPRINT]. Authorea. 2025, 10.22541\/au.175811469.99303481\/v1","journal-title":"Authorea"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251404505","article-title":"Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: two case reports and systematic review of reported cases","volume":"109","author":"Villarejo Galende A","year":"2026","unstructured":"Villarejo Galende A, Gonz\u00e1lez-S\u00e1nchez M, Hilario A, et al.. Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: two case reports and systematic review of reported cases. J Alzheimers Dis. 2026, 109:1099-116. 10.1177\/13872877251404505","journal-title":"J Alzheimers Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474674-a-severe-symptomatic-case-of-amyloid-related-imaging-abnormalities-after-donanemab-infusion","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T23:33:27Z","timestamp":1779060807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474674-a-severe-symptomatic-case-of-amyloid-related-imaging-abnormalities-after-donanemab-infusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.109045","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,17]]}}}